Evidence map›Paper›PMID 42370195›Full record

ArticleTheranostics2026

Peripheral blood immune profiling reveals key signatures in newly diagnosed NK/T cell lymphoma patients.

Dahui Li, Hongyuan Zou, Mingyu Wang, Na Tian, Chuanxu Liu, Wenhao Zhang, Shiyu Jiang, Ruiliang Zhu, Xiangyu Yang, Fangxia Li and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Dahui LiDepartment of Lymphoma and Medical Oncology, Fudan University Shanghai Cancer Center, Research Center for Lymphoma, Fudan University, Shanghai 200032, China.
Hongyuan ZouUniversity of Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China.
Mingyu WangUniversity of Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China.
Na TianUniversity of Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China.
Chuanxu LiuDepartment of Lymphoma and Medical Oncology, Fudan University Shanghai Cancer Center, Research Center for Lymphoma, Fudan University, Shanghai 200032, China.
Wenhao ZhangDepartment of Lymphoma and Medical Oncology, Fudan University Shanghai Cancer Center, Research Center for Lymphoma, Fudan University, Shanghai 200032, China.
Shiyu JiangDepartment of Lymphoma and Medical Oncology, Fudan University Shanghai Cancer Center, Research Center for Lymphoma, Fudan University, Shanghai 200032, China.
Ruiliang ZhuUniversity of Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China.
Xiangyu YangUniversity of Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China.
Fangxia LiUniversity of Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China.
Ying GaoState Key Laboratory of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Wendi WeiUniversity of Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China.
Ran JiaDepartment of Clinical Laboratory, Children's Hospital of Fudan University, Shanghai 201102, China.
Zihan JiangSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Yuanhua LiuState Key Laboratory of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Rong TaoDepartment of Lymphoma and Medical Oncology, Fudan University Shanghai Cancer Center, Research Center for Lymphoma, Fudan University, Shanghai 200032, China.
Xiaozhen LiangUniversity of Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Natural killer/T-cell lymphoma (NKTCL) is an aggressive Epstein-Barr virus (EBV)-associated non-Hodgkin lymphoma with a poor prognosis. Recent genomic and transcriptomic studies of tumor tissues have advanced our understanding of NKTCL pathogenesis, but the systemic immune profile at initial diagnosis remains incompletely elucidated. Methods: In this study, we characterized the immune landscape of peripheral blood mononuclear cells (PBMCs) from 20 newly diagnosed NKTCL patients and 12 healthy donors using single-cell RNA sequencing and confirmed our results through flow cytometry and PrimeFlow. Results: We identified a distinct proliferative-NK/T (Proli-NK/T) cell subset in NKTCL, characterized by high expression of cell cycle-related genes but lacking a malignant phenotype. Additionally, we observed a reduction in total and classical memory B cells, accompanied by enrichment of apoptosis and cell differentiation signatures. NK cells showed increased expression of HLA class II and activation markers, along with enhanced predicted interactions with CD4 Conclusions: We have uncovered the dynamic changes in PBMCs of newly diagnosed NK/T cell lymphoma patients and identified specific characteristics in patients with high intracellular EBV levels. Our findings provide new insights into the immunopathogenesis of NKTCL, offering valuable information for immune-based stratification and the development of therapeutic strategies.

Indexed as

Killer Cells, NaturalLeukocytes, MononuclearAdultAgedEpstein-Barr Virus InfectionsFemaleFlow CytometryHerpesvirus 4, HumanHumansMaleMiddle AgedNatural Killer T-CellsEBVNKTCLPBMCPrimeFlowsingle-cell RNA sequencing

Identifiers

PMID42370195
PMCPMC13295915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.